Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy
Boaz Wong(University of Ottawa), Jean‐Simon Diallo(University of Ottawa)
Cited by 23
Related Papers
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy
|Communications Biology|2020|16